Credit Suisse AG Grows Stock Position in Maximus, Inc. (NYSE:MMS)

Credit Suisse AG raised its holdings in shares of Maximus, Inc. (NYSE:MMS) by 7.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 59,743 shares of the health services provider’s stock after acquiring an additional 3,904 shares during the quarter. Credit Suisse AG owned approximately 0.10% of Maximus worth $4,702,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. LPL Financial LLC increased its stake in shares of Maximus by 2.9% during the 1st quarter. LPL Financial LLC now owns 115,979 shares of the health services provider’s stock worth $9,128,000 after purchasing an additional 3,291 shares in the last quarter. Great Lakes Retirement Inc. acquired a new position in shares of Maximus in the first quarter worth $222,000. Wintrust Investments LLC lifted its position in shares of Maximus by 3.6% in the first quarter. Wintrust Investments LLC now owns 4,360 shares of the health services provider’s stock valued at $343,000 after acquiring an additional 150 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Maximus by 17.8% during the first quarter. Tower Research Capital LLC TRC now owns 1,620 shares of the health services provider’s stock valued at $127,000 after acquiring an additional 245 shares during the last quarter. Finally, Boston Partners increased its position in Maximus by 10.0% during the 1st quarter. Boston Partners now owns 146,819 shares of the health services provider’s stock worth $11,763,000 after purchasing an additional 13,336 shares in the last quarter. Institutional investors and hedge funds own 99.30% of the company’s stock.

Maximus Trading Down 1.2 %

NYSE MMS opened at $80.41 on Wednesday. The company has a market cap of $4.89 billion, a P/E ratio of 28.72 and a beta of 0.69. Maximus, Inc. has a 12 month low of $54.46 and a 12 month high of $89.69. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.46 and a quick ratio of 1.46. The company has a 50-day moving average of $83.43 and a 200-day moving average of $81.86.

Maximus (NYSE:MMS) last issued its quarterly earnings results on Wednesday, August 2nd. The health services provider reported $0.78 EPS for the quarter, missing the consensus estimate of $1.14 by ($0.36). The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.20 billion. Maximus had a return on equity of 15.11% and a net margin of 3.56%. The business’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same period last year, the company posted $0.78 EPS. As a group, equities analysts predict that Maximus, Inc. will post 3.88 earnings per share for the current year.

Maximus Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, August 31st. Shareholders of record on Tuesday, August 15th will be given a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 1.39%. The ex-dividend date of this dividend is Monday, August 14th. Maximus’s dividend payout ratio (DPR) is presently 40.00%.

Insider Transactions at Maximus

In other news, Director Michael J. Warren sold 2,490 shares of the business’s stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $79.53, for a total transaction of $198,029.70. Following the completion of the sale, the director now owns 3,890 shares in the company, valued at approximately $309,371.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Bruce Caswell acquired 3,141 shares of Maximus stock in a transaction on Friday, August 4th. The shares were bought at an average price of $79.07 per share, for a total transaction of $248,358.87. Following the completion of the purchase, the chief executive officer now directly owns 210,484 shares in the company, valued at approximately $16,642,969.88. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael J. Warren sold 2,490 shares of the company’s stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $79.53, for a total value of $198,029.70. Following the completion of the sale, the director now directly owns 3,890 shares of the company’s stock, valued at approximately $309,371.70. The disclosure for this sale can be found here. Company insiders own 1.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on MMS. StockNews.com initiated coverage on shares of Maximus in a research note on Thursday, August 17th. They set a “hold” rating on the stock. Stifel Nicolaus initiated coverage on shares of Maximus in a research report on Friday, August 18th. They set a “buy” rating and a $102.00 target price on the stock. Finally, TheStreet downgraded Maximus from a “b” rating to a “c+” rating in a report on Tuesday, August 15th.

About Maximus

Maximus, Inc provides business process services (BPS) to government health and human services programs. It operates through three segments: U.S. Services, U.S. Federal Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.